Fluidigm Corporation today announced it ranked 185 on Deloitte’s Technology Fast 500™ list, which ranks the 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America from 2007 to 2011. Fluidigm grew 489% during this period. Fluidigm was the fastest growing Life Sciences company in the San Francisco Bay Area, according to the Fast 500™ rankings. The Life Sciences category includes Biotechnology/Pharmaceutical, Medical Devices, and Scientific/Technical Instrumentation. Fluidigm President and Chief Executive Officer Gajus Worthington attributes the company’s ranking and growth to life science researchers’ enthusiasm for Fluidigm’s industry-leading genetic analysis tools, which are used to explore the causes and characteristics of diseases at the level of a single cell. “Researchers increasingly understand that analyzing genetics at the single-cell level is crucial. In order to make sense of challenges and opportunities in healthcare ranging from cancer treatment to stem cell therapy, essential information can only be uncovered by looking at the DNA and RNA of every individual cell in a sample, rather than averaging the data of all the cells in the sample,” said Worthington. “As the field recognizes the importance of single-cell research, they are turning to Fluidigm’s market-leading products because we provide fully automated, cost-effective tools to conduct this research. We believe there are essentially an unlimited number of cells that need this level of scrutiny, so we are confident single-cell genomics will continue to drive Fluidigm’s growth for the foreseeable future.” Worthington added that Fluidigm is both delighted and honored to be recognized for its strong growth by being named to the Deloitte 2012 Technology Fast 500 list for the second year in a row. “It is a wonderful honor and we are thankful for this recognition of our performance to date,” said Worthington. “The companies on the Fast 500 list are among those that have demonstrated remarkable innovation, creativity and business savvy,” said Bill Ribaudo partner, Deloitte & Touche LLP and national TMT leader for audit and enterprise risk services (AERS). “As a result, these companies have continued to successfully forge ahead in a challenging economic environment. We applaud the leadership and employees of Fluidigm for this impressive accomplishment.”
“We are proud to honor the 2012 Technology Fast 500™ companies, and commend them for their outstanding growth,” said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications (TMT) leader. "These ground-breaking companies have outpaced their competition and are reinventing the way we do business today.”About Deloitte’s 2012 Technology Fast 500™ Technology Fast 500, conducted by Deloitte & Touche LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2007 to 2011. In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America. Use of Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements relating to market trends, our products and our future growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to market acceptance of our products, competition, our sales, marketing and research and development activities, changes in spending or budget priorities by customers, and risk associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm’s business and operating results are contained in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.
About FluidigmFluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including 13 different IFCs, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use). For more information, please visit www.fluidigm.com. Fluidigm, the Fluidigm logo and C 1 are trademarks or registered trademarks of Fluidigm Corporation.